

# Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009



A summary report from the Global  
Price Reporting Mechanism  
November 2009

## Contents

Abbreviations. . . . .	5
Table 1 : Median transaction price of <i>first-line</i> ARV medicines for adult treatment per patient per year (US\$/ppy) at a WHO recommended adult defined daily dose (DDD) . . . . .	6
Table 2: Median transaction price of <i>second-line</i> ARV medicines (US\$/ppy) for adult treatment at a WHO recommended adult DDD . . . . .	9
Table 3: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment ( <i>infant weighing 5 kg</i> ) at a WHO recommended paediatric DDD . . . . .	12
Table 4: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment ( <i>infant weighing 10 kg</i> ) at a WHO recommended paediatric DDD . . . . .	15
Table 5: Median transaction price (US\$) of smallest unit of <i>rapid tests</i> . . . . .	18
Table 6: Median transaction price of <i>ELISA and confirmatory tests</i> in 2008 and 2009 (US\$) . . . . .	19
References . . . . .	20

The Global Price Reporting Mechanism (GPRM) contains information on transaction prices and quantities of ARVs, tuberculosis drugs, malaria drugs and HIV, TB and Malaria diagnostics purchased by HIV/AIDS, TB and Malaria programmes in low-income countries\*, lower middle-income countries† and upper middle-income countries‡. The country classification is done using the World Bank Atlas calculation and classification method<sup>1,2</sup>, with the exception of sub-Saharan African countries which are considered low-income-countries as all have access to the lowest price of ARV's, according to the pricing policies of the ARV manufacturer<sup>5</sup>. The GPRM complements reports of price quotes from pharmaceutical companies<sup>3,4,5, 6,7,8</sup> as well as smaller sets of transaction prices published by other sources<sup>9,10,11,§</sup>.

This summary report features the transactions data of ARVs and HIV diagnostics in 2008 and the three first quarters of 2009, and is based on communications received by 30 October 2009. All transaction data have been compiled and stored in a searchable database by the AIDS Medicines & Diagnostics Service (AMDS) of WHO HIV/AIDS Department and are available at <http://www.who.int/hiv/amds/price/hdd/>.

The information provided in this report reflects transactions of:

- thirty-nine formulations commonly used for adult HIV treatment<sup>12,13</sup>
- thirty-three formulations for paediatric treatment recommended by WHO for the first and second-line regimens<sup>10,14</sup>
- twenty HIV serology tests (fifteen rapid, six ELISA, and four confirmatory) purchased by low-income, lower middle-income and upper-middle-income countries

The GPRM also contains data for less frequently used ARV formulations, medicine for opportunistic infections, medicines for malaria and tuberculosis treatment, and other health commodities related to the treatment of HIV, TB and malaria. However, this summary report does not include those data due to limited transaction volumes for the relevant commodities.

\* countries with a gross national income (GNI) per capita of US\$ 935 or less

† countries with a GNI per capita between US\$ 936 and US\$ 3,705

‡ countries with a GNI per capita between US\$ 3,706 and US\$ 11,455

§ The transaction data in the GPRM are provided by the following organizations: the Clinton Foundation; HIV/AIDS Initiative/UNITAID; the Global Fund to Fight AIDS, Tuberculosis, and Malaria; the International Dispensary Association; USAID/deliver (former John Snow Inc./deliver); Management Sciences for Health; Missionpharma; Supply Chain Management System; the United Nations Children's Fund; and the World Health Organization's Contracting and Procurement Service.

The prices in this report are reported as median prices with the inter-quartile range (IQR)\*\*. The combination of the median value and the IQR, rather than the mean  $\pm$  standard deviation, was selected to present the data in view of an asymmetrical distribution nature of the data. For the interpretation and use of the data in this report it is important to note that:

1) All prices are shown in US Dollars (US\$) per patient per year of a defined daily dose of each medicine for adults or children.

2) Taxes, tariffs, and/or International Commercial Terms (INCOTERMS: cost or condition of transport, insurance, etc.) are not consistently reported, and therefore are not considered. Previous investigations by the U.S. Government Accounting Office and Management Sciences for Health suggested that any variation in INCOTERMS constituted a 3% -15% increase over the factory or ex works (EXW) price<sup>8</sup>.

3) All transactions listed in the GPRM with a price of US\$0, or appearing as duplications, were considered to be either ARV donations or wrongly filed information. Such transactions were removed from the analysis, along with their corresponding purchase volumes.

4) When no price is mentioned in the tables, no transaction of the formulation were recorded for that specific category.

5) The prices in this report are international transaction prices, and not the prices paid by end-users at country level. End-user prices are often higher than international transaction prices due to tariffs, taxes, transportation costs, and mark-ups. However, in certain instances, end-user prices could be lower

than international transaction prices due to subsidies. More information on end-user prices can be found on the Health Action International website at <http://www.haiweb.org/medicineprices/><sup>15</sup>.

This summary report is intended to provide the pricing data of key ARVs and HIV diagnostics to governments, non-governmental organizations, donors, international organizations, academia, and

individuals or institutions directly involved or interested in the procurement of ARVs in resource-poor settings. Comments and suggestions would be greatly appreciated. Please send comments to Mr Boniface Dongmo Nguimfack at [dongmonguimfackb@who.int](mailto:dongmonguimfackb@who.int).



---

\*\* The IQR is a measure of statistical dispersion being equal to the difference between the third and first quartiles

## Table of abbreviations

International Non-proprietary Name (INN)	Abbreviation
abacavir	ABC
atazanavir	ATV
darunavir	DRV
didanosine	ddl
didanosine enteric-coated	ddl EC
efavirenz	EFV
emtricitabine	FTC
fos-amprenavir	FPV
indinavir	IDV
lamivudine	3TC
lopinavir	LPV
nelfinavir	NFV
nevirapine	NVP
ritonavir	RTV
saquinavir	SQV
stavudine	d4T
tenofovir	TDF
zidovudine	ZDV

Table 1 : Median transaction price of *first-line* ARV medicines for adult treatment per patient per year (US\$/ppy) at a WHO recommended adult defined daily dose (DDD)  
1a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
d4T 30 mg	2	19 (19-29)	30 (19-55)
d4T 40 mg*	2	36 (22-61)	-
3TC 150 mg	2	37 (37-48)	38 (32-73)
3TC 300 mg		59 (59-59)	-
NVP 200 mg	2	41 (40-49)	42 (39-67)
3TC+d4T 150+30mg	2	53 (49-61)	46 (44-53)
3TC+d4T 150+40mg*	2	74 (52-91)	-
3TC+NVP+d4T 150+200+30 mg	2	88 (83-93)	83 (77-87)
3TC+NVP+d4T 150+200+40 mg*	2	104 (79-151)	-
ZDV 300 mg	2	104 (99-114)	100 (94-147)
3TC+ZDV 150+300 mg	2	115 (114-129)	114 (107-145)
3TC+NVP+ZDV 150+200+300 mg	2	155 (144-164)	147 (139-155)
EFV 200 mg	3	194 (176-222)	189 (156-393)
EFV 600 mg	1	146 (138-179)	132 (106-187)
TDF 300 mg	1	166 (151-207)	152 (150-207)
TDF+3TC 300+300 mg	1	173 (173-173)	173 (1170-173)
TDF+FTC 300+200 mg	1	319 (208-319)	319 (319-319)
TDF+FTC+EFV 300+200+600 mg	1	613 (613-613)	613 (613-613)
ABC+3TC+ZDV 300+150+300 mg	2	-	718 (718-718)

\* d4T 40mg x 2/day is not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

## 1b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
d4T 30 mg	2	26 (23-30)	19 (19-37)
d4T 40 mg*	2	30 (30-31)	-
3TC 150 mg	2	40 (37-45)	35 (35-38)
3TC 30 mg		-	-
NVP 200 mg	2	48 (43-51)	43 (41-46)
3TC+d4T 150+30mg	2	60 (48-60)	33 (33-34)
3TC+d4T 150+40mg*	2	83 (72-93)	-
3TC+NVP+d4T 150+200+30 mg	2	100 (91-114)	61 (61-61)
3TC+NVP+d4T 150+200+40 mg*	2	103 (99-106)	-
ZDV 300 mg	2	113 (109-118)	103 (103-103)
3TC+ZDV 150+300 mg	2	124 (119-134)	83 (81-84)
3TC+NVP+ZDV 150+200+300 mg	2	169 (152-209)	116 (114-117)
EFV 200 mg	3	204 (191-394)	282 (168-416)
EFV 600 mg	1	169 (148-188)	92 (90-92)
TDF 300 mg	1	207 (177-256)	156 (150-365)
TDF+3TC 300+300 mg	1	173 (173-173)	-
TDF+FTC 300+200 mg	1	372 (355-541)	668 (414-931)
TDF+FTC+EFV 300+200+600 mg	1	1034 (1034-1034)	-
ABC+3TC+ZDV 300+150+300 mg	2	-	-

\* d4T 40mg x 2/day is not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

## 1c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
d4T 30 mg	2	33 (30-34)	19 (19-34)
d4T 40 mg*	2	467 (467-467)	-
3TC 150 mg	2	48 (45-383)	-
3TC 300 mg	2	-	-
NVP 200 mg	2	49 (48-69)	43 (42-45)
3TC+d4T 150+30mg	2	53 (53-53)	47 (47-51)
3TC+d4T 150+40mg*	2	-	-
3TC+NVP+d4T 150+200+30 mg	2	110 (96-166)	93 (93-93)
3TC+NVP+d4T 150+200+40 mg*	2	-	-
ZDV 300 mg	2	103 (99-107)	94 (92-97)
3TC+ZDV 150+300 mg	2	131 (126-252)	153 (106-153)
3TC+NVP+ZDV 150+200+300 mg	2	161 (161-178)	153 (153-153)
EFV 200 mg	3	195 (184-210)	156 (156-156)
EFV 600 mg	1	158 (158-210)	103 (90-115)
TDF 300 mg	1	238 (238-420)	150 (150-365)
TDF+3TC 300+300 mg	1		-
TDF+FTC 300+200 mg	1	-	-
TDF+FTC+EFV 300+200+600 mg	1	-	-
ABC+3TC+ZDV 300+150+300 mg	2	-	-

\* d4T 40mg x 2/day is not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

Table 2: Median transaction price of *second-line* ARV medicines (US\$/ppy) for adult treatment at a WHO recommended adult DDD

2a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
ABC 300 mg	2	317 (286-370)	280 (271-313)
ddl 100 mg	4	251 (187-310)	219 (187-310)
ddl 200 mg	2	242 (197-310)	199 (185-310)
ddl 250 mg	1	223 (214-223)	223 (172-223)
ddl 400 mg*	1	288 (279-288)	270 (270-288)
IDV 200 mg*	8	-	-
IDV 400 mg*	4	406 (350-445)	399 (336-445)
LPV+RTV 133+33 mg	6	497 (429-511)	493 (466-510)
LPV+RTV 200+50 mg	4	500 (500-535)	500 (500-574)
NFV 250 mg	10	1322 (1248-1928)	1553 (1553-2105)
RTV 100 mg**	2	84 (83-114)	78 (71-83)
SQV 200 mg*	10	2737 (1350-3000)	770 (756-805)
ATV 150mg*	2	-	-
ATV 200mg*	2	-	-
FPV 700 mg	2	-	-

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as booster of other protease inhibitors only

## 2b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
ABC 300 mg	2	350 (313-374)	304 (304-420)
ddl 100 mg	4	212 (187-235)	192 (187-254)
ddl 200 mg	2	238 (233-794)	852 (852-852)
ddl 250 mg	1	799 (675-874)	179 (179-179)
ddl 400 mg	1	1267 (507-1302)	264 (258-269)
IDV 200 mg*	8	456 (456-457)	-
IDV 400 mg*	4	446 (389-457)	363 (363-363)
LPV+RTV 133+33 mg	6	1107 (544-1122)	1000 (1000-1000)
LPV+RTV 200+50 mg	4	574 (574-1000)	1084 (740-1173)
NFV 250 mg	10	2631 (2258-2631)	2763 (2733-2793)
RTV 100 mg**	2	283 (99-811)	841 (764-871)
SQV 200 mg*	10	2704 (2410-2767)	2630 (2630-2630)
ATV 150mg*	2	469 (450-488)	4353 (4210-4497)
ATV 200mg*	2	437 (436-438)	-
FPV 700 mg	2	3215 (1430-5000)	1682 (1682-1682)

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as a booster of other protease inhibitors only

## 2c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or capsules)	2008	2009
ABC 300 mg	2	370 (353-401)	271 (271-271)
ddl 100 mg	4	462 (242-1100)	-
ddl 200 mg	2	220 (217-235)	-
ddl 250 mg	1	997 (613-997)	-
ddl 400 mg*	1	1269 (1129-1386)	-
IDV 200 mg*	8	-	-
IDV 400 mg*	4	538 (439-636)	-
LPV+RTV 133+33 mg	6	994 (586-2016)	-
LPV+RTV 200+50 mg	4	1391 (679-4210)	-
NFV 250 mg	10	4840 (1470-4840)	-
RTV 100 mg**	2	329 (313-346)	-
SQV 200 mg*	10	2210 (2164-2257)	-
ATV 150mg*	2	511 (511-511)	-
ATV 200mg*	2	-	-
FPV 700 mg	2	1284 (1284-1287)	

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as a booster of other protease inhibitors only

Table 3: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment (*infant weighing 5 kg*) at a WHO recommended paediatric DDD 3a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	4	91 (91-100)	92 (91-113)
ddl 10 mg/ml	8	362 (361-368)	312 (249-312)
ddl 25 mg	4	170 (170-170)	170 (170-170)
ddl 50 mg	2	112 (112-122)	116 (86-116)
EFV 30 mg/ml	3.25	116 (88-116)	112 (112-112)
EFV 50 mg	2	18 (16-37)	67 (59-79)
3TC 10 mg/ml	6	59 (59-71)	16 (16-20)
LPV+RTV 80+20 mg/ml	2	100(100-153)	100 (94-100)
NFV 50 mg/g	15	1421(1391-1450)	1318 (1318-1318)
NFV 250 mg	4	542(526-1000)	621 (621-621)
NVP 10 mg/ml	12	35 (35-40)	35 (35-69)
d4T 1 mg/ml	12	31 (29-53)	29 (29-31)
ZDV 10 mg/ml	12	40 (39-72)	39 (37-70)
3TC+d4T 20+5 mg	3	37 (37-37)	-
3TC+d4T 40+10 mg	1.5	-	-
3TC+NVP+d4T 20+35+5 mg	3	49 (49-49)	-
3TC+NVP+d4T 40+70+10 mg	1.5	48 (48-48)	-
3TC+d4T 30+6 mg	2	26 (22-26)	23 (23-23)
3TC+d4T 60+12 mg	1	25(22-26)	20 (20-21)
3TC+NVP+d4T 30+50+6 mg	2	30(26-30)	29 (26-29)
3TC+NVP+d4T 60+100+12 mg	1	27 (24-28)	26 (24-26)
3TC+ZDV 30+60 mg	2	41 (41-41)	41 (41-44)
3TC+NVP+ZDV 30+50+60 mg	2	53 (53-53)	53 (53-53)

## 3b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	4	116 (100-142)	122 (106-137)
ddl 10 mg/ml	8	836 (692-980)	934 (431-978)
ddl 25 mg	4	135 (97-390)	75 (51-98)
ddl 50 mg	2	-	88 (88-109)
EFV 30 mg/ml	3.25	-	119 (119-119)
EFV 50 mg	2	-	59 (59-59)
3TC 10 mg/ml	6	38 (21-54)	16 (16-16)
LPV+RTV 80+20 mg/ml	2	228 (217-500)	200 (200-369)
NFV 50 mg/g	15	1779 (992-1779)	1403 (821-1779)
NFV 250 mg	4	903 (473-1053)	667 (318-911)
NVP 10 mg/ml	12	84 (58-122)	84 (38-228)
d4T 1 mg/ml	12	56 (51-117)	32 (32-57)
ZDV 10 mg/ml	12	78( 49-91)	39 (37-39)
3TC+d4T 20+5 mg	3	-	-
3TC+d4T 40+10 mg	1.5	-	-
3TC+NVP+d4T 20+35+5 mg	3	-	-
3TC+NVP+d4T 40+70+10 mg	1.5	-	-
3TC+d4T 30+6 mg	2	24 (23-25)	36 (31-41)
3TC+d4T 60+12 mg	1	25 (24-26)	26 (23-26)
3TC+NVP+d4T 30+50+6 mg	2	53 (53-53)	29 (29-29)
3TC+NVP+d4T 60+100+12 mg	1	27 (27-28)	28 (27-28)
3TC+ZDV 30+60 mg	2	41 (41-41)	41 (41-43)
3TC+NVP+ZDV 30+50+60 mg	2	53 (53-53)	53 (53-53)

## 3c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	4	100 (95-100)	-
ddl 10 mg/ml	8	940 (427-974)	-
ddl 25 mg	4	224 (222-250)	-
ddl 50 mg	2	-	-
EFV 30 mg/ml	3.25	113 (113-113)	-
EFV 50 mg	2	-	-
3TC 10 mg/ml	6	55 (55-72)	16 (16-20)
LPV+RTV 80+20 mg/ml	2	250 (236-392)	-
NFV 50 mg/g	15	-	-
NFV 250 mg	4	1936 (558-1936)	-
NVP 10 mg/ml	12	87 (62-98)	35 (35-35)
d4T 1 mg/ml	12	566 (310-823)	33 (33-33)
ZDV 10 mg/ml	12	38 (36-94)	39 (37-72)
3TC+d4T 20+5 mg	3	-	-
3TC+d4T 40+10 mg	1.5	-	-
3TC+NVP+d4T 20+35+5 mg	3	-	-
3TC+NVP+d4T 40+70+10 mg	1.5	-	-
3TC+d4T 30+6 mg	2	-	-
3TC+d4T 60+12 mg	1	-	-
3TC+NVP+d4T 30+50+6 mg	2	-	-
3TC+NVP+d4T 60+100+12 mg	1	-	-
3TC+ZDV 30+60 mg	2	41 (41-41)	-
3TC+NVP+ZDV 30+50+60 mg	2	-	-

Table 4: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment (*infant weighing 10 kg*) at a WHO recommended paediatric DDD 4a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	10	228 (228-251)	228 (205-229)
ddl 10 mg/ml	12	543 (541-552)	467 (374-467)
ddl 25 mg	5	213 (212-213)	213 (213-213)
ddl 50 mg	3	173 (132-173)	173 (129-173)
ddl 100 mg	2	125 (94-155)	118 (94-155)
ddl 125 mg	1	94 (93-95)	-
EFV 50 mg	4	118 (118-135)	134 (109-166)
EFV 200 mg	1	65 (59-74)	62 (52-109)
3TC 10 mg/ml	10	30 (27-53)	27 (27-30)
LPV+RTV 80+20 mg/ml	3	150 (150-160)	150 (141-150)
LPV+RTV 100+25 mg	3	188 (187-188)	-
LPV+RTV 133+33 mg	2	166 (143-170)	164 (155-170)
LPV+RTV 200+50 mg	1.5	188 (188-215)	-
NFV 250 mg	6	780 (813-1407)	932 (932-932)
NVP 10 mg/ml	20	59 (59-67)	59 (58-114)
NVP 200 mg	1	21 (20-24)	21 (19-24)
d4T 15 mg	2	18 (18-23)	18 (18-23)
d4T 20 mg	2	21 (21-27)	18 (18-23)
ZDV 10 mg/ml	20	67 (65-115)	65 (61-109)
ZDV 100 mg	2	37 (35-44)	36 (35-42)
3TC+d4T 150+30 mg	1	26 (24-30)	23 (22-26)
3TC+NVP+d4T 150+200+30 mg	1	44 (42-46)	41 (38-43)
3TC+d4T 40+10 mg	3	61 (61-61)	61 (61-61)
3TC+d4T 20+5 mg	5	26 (24-30)	53 (53-53)
3TC+NVP+d4T 20+35+5 mg	5	82 (82-82)	82 (82-82)
3TC+NVP+d4T 40+70+10 mg	3	96 (96-96)	96 (96-96)
3TC+d4T 30+6 mg	4	51 (45-53)	46 (46-46)
3TC+d4T 60+12 mg	2	50 (44-51)	40 (40-41)
3TC+NVP+d4T 30+50+6 mg	4	59 (52-61)	58 (52-58)
3TC+NVP+d4T 60+100+12 mg	2	54 (47-55)	52 (47-52)
3TC+ZDV 30+60 mg	4	83 (83-83)	83 (83-86)
3TC+NVP+ZDV 30+50+60 mg	4	105 (105-105)	105 (105-105)

### 4b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	10	278 (243-363)	229 (228-229)
ddl 10 mg/ml	12	1140 (1126-1444)	-
ddl 25 mg	5	168 (121-487)	151 (151-151)
ddl 50 mg	3	132 (132-730)	129 (129-129)
ddl 100 mg	2	106 (94-118)	110 (94-134)
ddl 125 mg	1	86 (74-99)	-
EFV 50 mg	4	154 (146-169)	-
EFV 200 mg	1	68 (64-131)	131 (131-131)
3TC 10 mg/ml	10	63 (36-90)	27 (26-47)
LPV+RTV 80+20 mg/ml	3	342 (326-750)	300 (300-353)
LPV+RTV 100+25 mg	3	-	-
LPV+RTV 133+33 mg	2	181 (178-369)	3333 (333-333)
LPV+RTV 200+50 mg	1.5	-	-
NFV 250 mg	6	1579 (1355-1579)	-
NVP 10 mg/ml	20	137 (77-145)	261(85-380)
NVP 200 mg	1	24 (21-25)	21 (21-21)
d4T 15 mg	2	18 (18-21)	-
d4T 20 mg	2	18 (18-21)	-
ZDV 10 mg/ml	20	146 (73-146)	65 (60-65)
ZDV 100 mg	2	43 (37-48)	35 (35-35)
3TC+d4T 150+30 mg	1	30 (28-38)	23 (23-23)
3TC+NVP+d4T 150+200+30 mg	1	50 (46-57)	41 (41-42)
3TC+d4T 40+10 mg	3	61 (61-61)	-
3TC+d4T 20+5 mg	5	53 (53-53)	-
3TC+NVP+d4T 20+35+5 mg	5	82 (82-82)	-
3TC+NVP+d4T 40+70+10 mg	3	96 (96-96)	-
3TC+d4T 30+6 mg	4	49 (47-51)	92 (92-92)
3TC+d4T 60+12 mg	2	51 (49-51)	51 (46-51)
3TC+NVP+d4T 30+50+6 mg	4	52 (52-52)	58 (58-58)
3TC+NVP+d4T 60+100+12 mg	2	54 (54-55)	55 (54-55)
3TC+ZDV 30+60 mg	4	83 (83-83)	88 (88-88)
3TC+NVP+ZDV 30+50+60 mg	4	105 (105-105)	105 (105-105)

## 4c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)		
	DDD (tablets or ml)	2008	2009
ABC 20 mg/ml	10	249 (238-249)	-
ddl 10 mg/ml	12	-	-
ddl 25 mg	5	121 (121-121)	-
ddl 50 mg	3	97 (80-115)	-
ddl 100 mg	2	176 (121-268)	-
ddl 125 mg	1	-	-
EFV 50 mg	4	122 (122-122)	118 (118-118)
EFV 200 mg	1	62 (61-70)	52 (52-52)
3TC 10 mg/ml	10	92 (76-106)	29 (28-33)
LPV+RTV 80+20 mg/ml	3	350 (339-361)	-
LPV+RTV 100+25 mg	3	187 (187-187)	-
LPV+RTV 133+33 mg	2	933 (331-934)	-
LPV+RTV 200+50 mg	1.5	-	1278 (1278-1278)
NFV 250 mg	6	2904 (2398-2904)	-
NVP 10 mg/ml	20	67 (67-160)	-
NVP 200 mg	1	24 (24-32)	21 (21-22)
d4T 15 mg	2	-	18 (18-18)
d4T 20 mg	2	20 (20-20)	18 (18-18)
ZDV 10 mg/ml	20	61 (61-152)	65 (63-102)
ZDV 100 mg	2	-	-
3TC+d4T 150+30 mg	1	26 (26-26)	23 (23-25)
3TC+NVP+d4T 150+200+30 mg	1	42 (42-52)	46 (46-46)
3TC+d4T 40+10 mg	3	-	-
3TC+d4T 20+5 mg	5	-	-
3TC+NVP+d4T 20+35+5 mg	5	-	-
3TC+NVP+d4T 40+70+10 mg	3	96 (96-96)	-
3TC+d4T 30+6 mg	4	-	-
3TC+d4T 60+12 mg	2	-	-
3TC+NVP+d4T 30+50+6 mg	4	-	-
3TC+NVP+d4T 60+100+12 mg	2	-	-
3TC+ZDV 30+60 mg	4	-	-
3TC+NVP+ZDV 30+50+60 mg	4	-	-

Table 5: Median transaction price (US\$) of smallest unit of *rapid tests*

Product name	Median transaction price (25th -75th Quartile range) (US\$/ppy)	
	2008	2009
Capillus HIV ½	1.39 (1.10 - 1.39)	1.53 (1.41 - 1.53)
Clearview Complete HIV 1/2	3.00 (3.00 - 3.00)	3.00 (3.00 - 3.00)
Determine HIV ½	0.80 (0.72 - 0.80)	0.80 (0.80 - 0.80)
DoubleCheck Gold HIV 1/2	0.74 (0.69 - 0.78)	0.83 (0.83 - 0.83)
First Response HIV 1.2.0	0.65 (0.65 - 0.65)	0.76 (0.75 - 0.76)
Genie II HIV ½	2.00 (1.90 - 2.00)	2.70 (2.67 - 2.75)
HIV 1/2 Antibody Colloidal Gold	0.46 (0.46 - 0.46)	0.46 (0.46 - 0.46)
HIV Tri-dot	1.05 (1.05 - 1.05)	1.17 (1.15 - 1.18)
ImmunocombII Bispot HIV 1/2	1.67 (1.67 - 1.67)	2.02 (1.84 - 2.19)
OraQuick HIV ½	3.50 (3.50 - 3.50)	3.50 (3.50 - 3.50)
Retrocheck HIV test	0.55 (0.55 -0.55)	0.55 (0.55 -0.55)
SD Bioline HIV ½ 3.0	0.80 (0.80 - 0.80)	0.80 (0.80 - 0.80)
Serodia HIV ½	1.18 (1.18 - 1.18)	1.18 (1.18 - 1.18)
Stat-Pak HIV 1/2	1.35 (1.35 - 1.35)	0.79 (0.79 - 0.79)
Uni-Gold HIV	1.60 (1.27 - 1.60)	1.70 (1.64 - 1.81)

Table 6: Median transaction price of *ELISA and confirmatory tests* in 2008 and 2009 (US\$)

6a) ELISA tests

Product name	Median transaction price (25th -75th Quartile range)	
	2008	2009
Enzygnost Anti-HIV 1/2	1.00 (1.00-1.00)	1.57 (1.57 - 1.57)
Genedia HIV Ag-Ab	0.33 (0.33-0.33)	0.33 (0.33 - 0.33)
Genscreen HIV 1/2 V2	0.52 (0.52-0.52)	2.46 (2.46 - 2.46)
HIV EIA Elisa	0.40 (0.40-0.40)	0.64 (0.64 - 0.64)
Murex HIV Ag-Ab	1.25 (0.94-1.43)	1.89 (1.54 - 1.89)
Vironostika HIV Uni-form II	1.59 (1.39-1.80)	1.16 (1.14 - 1.45)

6b) Confirmatory tests

Product name	Median transaction price (25th -75th Quartile range)	
	2008	2009
HIV BLOT 2.2	9.44 (9.44-9.44)	13.61 (13.38 - 13.83)
Inno-Lia HIV 1/2	14.0 (14.0-14.0)	18.75 (18.63 - 20.62)
New LAV Blot	13.65 (13.65-13.65)	13.65 (13.65-13.65)
Pepti-LAV	15.75 (15.75-15.75)	15.75 (15.75-15.75)

### References

1. World Bank Group - Data and statistics: Country Classification; Income group. Washington June 2009  
<http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20421402~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html>
2. World Bank Group -Data and statistics: World Bank Atlas Method Washington June 2009  
<http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20452009~menuPK:64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html>
3. "Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS";: A Joint UNICEF, UNAIDS, WHO, MSF Project. United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS, World Health Organization, Médecins Sans Frontières. Geneva, Switzerland. 2006 (data only).  
<http://www.unicef.org/supply/files/sourcesandprices2005.pdf>
4. Sources and Prices of selected medicines for children including therapeutic food, dietary vitamin and mineral supplementation. UNICEF in collaboration with WHO, January 2009  
[http://www.unicef.org/supply/files/Sources\\_and\\_prices\\_of\\_selected\\_medicines.pdf](http://www.unicef.org/supply/files/Sources_and_prices_of_selected_medicines.pdf)
5. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries (11th edition). Campaign for Access to Essential Medicines. Médecins Sans Frontières. Geneva, Switzerland. July 2008  
[http://www.accessmed-msf.org/fileadmin/user\\_upload/diseases/hiv-aids/Untangling\\_the\\_Web/UTW10\\_RSep\\_horizontal.pdf](http://www.accessmed-msf.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/UTW10_RSep_horizontal.pdf)
6. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries (Update to 11th edition). Campaign for Access to Essential Medicines. Médecins Sans Frontières. Geneva, Switzerland. January 2009
7. Global HIV/AIDS Epidemic: Selection of Antiretroviral Medications Provided Under US Emergency Plan is Limited. Report to Congressional Requesters. United States Government Accountability Office. January 2005.
8. The Global Fund Secretariat The Price & Quality Reporting (PQR) system  
<http://pqr.theglobalfund.org/PQRWeb/Reports/FullPQRReport.aspx>
9. Purchase Price Report. The Global Fund to Fight AIDS, TB, and Malaria. Geneva, Switzerland. September 2007.  
<http://web.theglobalfund.org/ReportServer/Pages/ReportViewer.aspx?/PRM/Product+Price+Report>

10. AFRO Essential Medicines Price Indicator. World Health Organization Regional Office for Africa (WHO AFRO). Brazzaville, Republic of Congo. December 2003.
11. International Drug Price Indicator Guide, 2008 edition. Guide produced in collaboration with the World Health Organization and supported by the Strategies for Enhancing Access to Medicines (SEAM) Program, which is funded by the Bill & Melinda Gates Foundation. Cambridge, MA 2009  
<http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=Dmp&language=English>
12. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access: Recommendations for a public health approach, 2006 revision. World Health Organization. Geneva, Switzerland. 2006.  
<http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf>
13. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. World Health Organization. Geneva, Switzerland. 2004.  
[http://www.who.int/hiv/pub/prev\\_care/en/arvrevision2003en.pdf](http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf)
14. Antiretroviral therapy of HIV infection in infants and children: towards universal access: Recommendations for a public health approach, 2006 revision. World Health Organization. Geneva, Switzerland. 2006.  
<http://www.who.int/entity/hiv/pub/guidelines/paediatric020907.pdf>
15. Medicine Prices. Health Action International (HAI) and the World Health Organization Department of Essential Drugs and Medicines Policy published a working draft of a manual to collect and analyse the prices people pay for a selection of important medicines, as well as identifying price components (taxes, mark-ups etc.) and the affordability and availability of key medicines. May 2003.  
<http://www.haiweb.org/medicineprices/>

Transaction Prices for Antiretroviral Medicines and  
HIV Diagnostics from 2008 to October 2009

